low mortality rate from prostate cancer suggests that public awareness of early detection and advanced treatments of prostate cancer have begun to affect prostate cancer outcomes.
Introduction
Prostate cancer is the most common type of cancer (other than the skin) and the second leading cause of cancer mortality in American men. One man in 6 will develop prostate cancer during his lifetime, and 1 man in 34 will die of the disease. 1 In 2010 in the United States, an estimated 217,730 new cases will be diagnosed, and 32,050 men will die of the disease. 2 Although prostate cancer can be found early through PSA screening, this test is not 100% accurate, and false-positive results can lead to unnecessary prostate biopsy tests. However, a rectal examination and serum prostate-specific antigen ( PSA) screening are two main clinical diagnostic tools. However, due to their limited accuracies, these methods cannot reliably identify early-stage prostate cancer. Therefore, the identification of biomarkers that can facilitate the diagnosis of prostate cancer at the early stages could improve the current standard of treatments. The second challenge is to determine if a patient is presenting with aggressive or indolent prostate cancer. This is critically important information, given the significant morbidity associated with treatment interventions, and could eventually help distinguish men who need intensive treatment from those who may be better served by watchful waiting. Currently, the level of PSA, the clinical stage, and the grade of tumor (Gleason score) are used to estimate prognosis and determine treatment modalities. Although they are useful, additional biomarkers are needed to better predict the outcome of prostate cancer. Therefore, molecular biomarkers should help in determining who may need a prostate biopsy, which treatments a patient will undergo, and who may have a recurrence.
Role of DNA Methylation in Prostate Cancer
Tumorigenesis and progression of prostate cancer are results of the accumulation of genetic and epigenetic alterations. Although genetic changes are involved in the inactivation of genes with important anticancer functions (eg, tumor suppressor and DNA repair genes), DNA methylation in a promoter region is an important epigenetic mechanism for the downregulation (silencing) of expression of these genes. DNA methylation in the promoter region of tumor suppressor genes appears to occur at early stages of carcinogenesis and arises with various frequencies. Therefore, epigenetic changes have the potential to be a new generation of biomarkers. Several types of epigenetic changes have been reported for prostate cancer including DNA hypermethylation, loss of imprinting, and altered histone modification patterns.
DNA methylation in the promoter of a number of genes occurs frequently in prostate tumors but rarely in normal prostate tissues. CpG islands are CpG-rich areas of 200 base-pairs to several kilo bases in length, usually located near the promoters of highly expressed genes, and they are the sites of almost all hypermethylation in human tumors, 3 including the prostate. A common molecular feature associated with tumorigenesis is hypermethylation of cytosines 5′ to guanosines (CpG) within the regulatory (promoter) region of suppressor gene genomic DNA. [4] [5] [6] [7] [8] 5-Methyl cytosine is unstable and mutates to thymine, and methylated CpG sites degrade to TpG/CpA. In tumors, many CpG islands exhibit aberrant hypermethylation, resulting in gene silencing (Figure) . Many of the silenced genes encode proteins that are tumor suppressor genes involved in tumorigenesis and progression.
DNA Methylation Detection Methods
Multiple molecular biology techniques are available for detecting the DNA methylation pattern in genomic DNA. 9 Based on the type of technique used, two major groups of detection methods are available.
Hybridization Method
This method is a combination of Southern blot and methylation-sensitive restriction enzymes treatment together with polymerase chain reaction (PCR). Since some restriction enzymes are methylation-sensitive, these enzymes cannot digest methylated target sequence. Combined with Southern blot technique, the hybrid ization method can assess the overall methylation status of target CpG sites. Major limitations of this technique are requirement of a large amount of genomic DNA and limited information of promoter methylation. At least 5 μg of genomic DNA is needed to analyze the methylation status. Results from this technique provide information for target CpG sites of methylation-sensitive restriction enzymes.
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PCR Method
In order to detect methylated CpG sites, DNA samples are modified by sodium bisulfite. Sodium bisulfite deaminates cytosine and transforms into uracil. 10 Methylated cytosine, however, is not transformed by bisulfite treatment. Currently, methylation-specific PCR (MSP) and quantitative real-time MSP are two major techniques detecting methylation with the use of bisulfite-modified DNA. These PCR methods can be performed in a short time without a large amount of DNA sample. Also, they provide specific and sensitive results, especially using quantitative real-time MSP, which has sufficient sensitivity to detect methylation of 0.1% of alleles. However, like other PCR-based techniques, these methods may provide false-positive results.
11
Hypermethylated Genes in Prostate Tumor
The majority of previous publications in epigenetic research in prostate cancer focused on DNA hypermethylation. Indeed, gene-silencing is more common by DNA hypermethylation in the promoter region than by DNA mutations in carcinogenesis. Numerous studies on various hypermethylated genes in different cancers suggest a key part of the carcinogenesis and progression of cancer. 12 Currently, over 30 genes have been investigated for their frequencies of hypermethylation and for their potential role in prostate cancer (Table) . Many of these hypermethylated genes are tumor suppressor genes that are coded for the proteins that regulate the cell cycle and/or promote apoptosis. The functions of tumor suppressor genes in prostate cancer fall into five major categories: DNA repair, apoptosis, cell cycle, corticosteroid hormonal response, and invasion/metastasis. Defected function of these genes by promoter hypermethylation can contribute to the carcinogenesis and progression of prostate cancer.
DNA Repair Gene
Although the specific causes of prostate cancer are not known, androgens, estrogens, inflammation, and DNA repair capacity have been implicated. DNA is constantly damaged by endogenous oxygen free radicals and exogenous chemicals. DNA mutations are estimated to spontaneously occur 20,000 to 40,000 times every day. 13, 14 The DNA repair process is important to the survival of the cell. Therefore, different repair pathways are available to reverse the different types of DNA damage. More than 150 DNA repair enzymes participate in this process. 15 Defects in these DNA repair pathways may increase persistent mutations in daughter cell generations, genomic instability, and ultimately a prostate cancer risk.
Among several distinct DNA repair pathways, the direct reversal repair pathway may be important in carcinogenesis in the prostate. Methylguanine DNA methyltransferase (MGMT), the only known enzyme in the direct reversal repair pathway, leads to the direct restoration of the natural chemical composition of DNA without the need for genomic reconstruction. Therefore, defective MGMT activity is associated with an increased mutation. 16 Reports regarding MGMT methylation in prostate tumor tissues have been inconsistent. While three studies reported a low frequency of MGMT promoter hypermethylation (0% to 2%) in prostate tumor tissues, 17-19 others observed higher prevalence of hypermethylation (19% to 76%). [20] [21] [22] Two investigator groups reported 15% and 19% MGMT hypermethylation frequencies in urine sediment samples collected from prostate cancer patients. 27, 35 These data suggest that MGMT promoter methylation can be a potential biomarker for early detection and surveillance of prostate cancer. However, larger studies will be necessary to resolve these inconsistent results.
Cell Cycle Genes
The cell cycle pathway regulates cell growth. One of the distinguishing characteristics of tumor cells is uncontrolled growth. Many genes act as checkpoints that regulate the cell cycle. Defective cell cycle genes may lead to the carcinogenesis and progression of prostate cancer. 23 The tumor suppressor gene CDKN2 is one of the cyclin-dependent kinase inhibitors (CDKIs). CDKN2A (p16INK4), a key protein in the signaling pathway, can be damaged by a variety of genetic and epigenetic changes including hypermethylation in prostate cancer. Aberrant CDKI expression is observed in many tumor tissues including prostate. 20, 21, 24 Results regarding the frequency of CDKN2A promoter methylation are inconsistent in prostate tumors, ranging from 3% to 77%. Although there was no significant association between CDKN2A low expression and increased CDKN2A exon 2 methylation, the exon 2 methylation may be a potential biomarker for prostate tumor. 24 These results were confirmed by other investigators. Konishi et al 21 observed that methylation occurred in the promoter region in 9% of samples and in exon 2 in 66% of tumors. Jerónimo et al 20 found that the CDKN2A gene was frequently methylated in tumor tissue (77%) and in benign prostatic hyperplasia (BPH). These data support p16 methylation as a potential biomarker for an early detection of prostate cancer.
Another CDKI, the CDKN2A (p14ARF) promoter, has been methylated in various cancers, 30 The RAS family of proto-oncogenes plays a key role in signal transduction pathways involved in cellular proliferation and survival, interacting with other regulatory circuits of cell growth and death. RAS association domain family protein 1 isoform A (RASSF1A) is known as a tumor suppressor gene. The RASSF1 protein was known to be associated with the DNA repair proteins and with the apoptotic effect. 36 Inactivation by methylation of RASSF1A may deregulate the DNA repair pathway and cell cycle control in the tumor. The RASSF1A gene is silenced by aberrant methylation of the promoter in a large fraction of various cancers including prostate. 37 In prostate tumors, RASSF1A promoter methylation is a common event, occurring in 49% to 99% of tumor tissues.
17,19,20,22,27,28,37-39 RASSF1A promoter methylation is also associated with aggressive prostate cancer.
17,22,37
Others cell cycle genes -CD44, cyclin D2 (CCND2), lipoprotein lipase (LPL), endothelin B receptor (EDNRB), hypermethylated in cancer 1 (HIC1), pairedlike homeodomain transcription factor 2 (PITX2), and prostaglandin-endoperoxidase synthase 2 (PTGS2) -are often have a lower expression in prostate tumor tissues than in adjacent normal tissues. These low expressions are significantly correlated with promoter methylation level. [40] [41] [42] [43] [44] [45] Furthermore, expression of these genes and their promoter methylation may correlate with the tumorigenesis, progression, and clinicopathological features of prostate cancer. [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] Many studies observed relatively high frequencies of promoter methylation in these genes: CD44 (32% to 78%), 39 The frequencies of methylation of these genes, with the exception of EDNRB and HIC1, were significantly higher in prostate tumors than in normal tissues. 42, 43, 49, 55, 57 Together, promoter methylation of these genes is a good candidate as a useful prostate cancer biomarker for the identification of the more aggressive prostate cancer that might benefit from different therapeutic modalities. However, the methylation status of EDNRB and HIC1 in prostate tumors parallels the respective normal tissue, although a high proportion of tumors are methylated. 18, 19, 39, [58] [59] [60] Therefore, DNA methylation sites in EDNRB and HIC1 are not good candidates for a marker for prognostic marker for prostate cancer progression and an intervention target for prostate cancer.
Apoptosis Genes
Programmed cell death (apoptosis) is a critical process for carcinogenesis in human. Typical morphological characteristics of apoptosis are damages of the plasma membrane, condensation and fragmentation of the nucleus, and DNA fragmentation. 61 A major component of the apoptosis pathway is the caspase family. However, other genes, including death-associated protein kinase (DAPK), fragile histidine triad (FHIT), solute carrier family 5A8 (SLC5A8), vesicular monoamine transporter 2 (SLC18A2), and tumor necrosis factor receptor superfamily, member 10C (TNFRSF10C), are also involved in this pathway. A repressed expression of these genes by hypermethylation in the promoter region has been shown for prostate cancer. [17] [18] [19] 35, [62] [63] [64] [65] However, DAPK and FHIT may have a limited value due to a persistently low frequency of methylation in tumors and normal tissues. [17] [18] [19] 35 SLC5A8, SLC18A2, and TNFRSF10C were found to be hypermethylated in 50% to 88% of prostate cancers and significantly downregulated in tumor compared with normal prostate tissues. 11, [62] [63] [64] 66, 67 Expression of SLC18A2 and TNFRSF10C is negatively associated with biochemical recurrence after radical prostatectomy. 63, 68 Corticosteroid Hormonal Response Genes The specific causes of prostate cancer are not known, but multiple etiological factors, including genetics, hormones, diet, infection, and environmental exposures, are thought to play significant roles. Although the precise role of androgens and their receptors in the carcinogenesis and progression of prostate cancer has not been fully investigated, previous studies suggest that these genes are important. 69, 70 Differences in the activities of these enzymes are determined to a large extent by genetic and epigenetic changes in the genes encoding them.
It is known that androgens stimulate the growth of prostate cells through the androgen receptor (AR). 71 While silencing of AR expression decreases growth and induces apoptosis in vitro, [72] [73] [74] overexpression of the AR also induces growth inhibition and apoptosis. 75 In addition to prostatectomy and radiation therapy, androgen deprivation is one of the most effective treatments for prostate cancer. However, many advanced prostate cancer cells can survive in a low androgen environment due to a high expression of the androgen receptor. 76 AR is one of the most frequently overexpressed proteins in the androgen-independent cases. 77 Feldman and Feldman 76 suggested five different possible pathways that lead to development of androgen-independent status. Several groups found AR promoter methylation in 8% to 39% of the prostate tumor tissues. 18, [78] [79] [80] [81] Frequencies of AR promoter methylation are higher in androgen-independent cases than in primary prostate tumor tissues. 78, 80 The role of estrogen in the carcinogenesis of prostate tissues is not clear. However, a loss of expression of the estrogen receptor (ER)-β was induced by promoter methylation during the development of prostate cancer. 82 The biological actions of estrogens are meditated by the ER. Two ERs are highly homologous DNA-binding domains but different N-terminus and ligand-binding domains. Both ERs, ER-α and ER-β, are downregulated in prostate tumor tissues. 83, 84 Promoter methylation is the primary mechanism responsible for low expression of ERs. 79, 85, 86 ER-α expression is associated with a poor prognosis for hormonal therapy. 87 ER-β is the main subtype in the prostate tissue and may serve as a tumor suppressor gene since ER-β protects against uncontrolled cell proliferation in normal prostate cells. 86 However, high expression of ER-β in prostate tumors is associated with increased risk for recurrence and distant metastasis. 84, 88 Therefore, ER-β may have multiple roles in carcinogenesis and progression. The frequency of ER promoter methylation ranges from 19% to 90% in prostate tumors.
19,89-91 The extent of ER promoter methylation is significantly higher in prostate tumors than in the BPH samples. 89, 90 Retinoic acid receptor β (RARβ) is known as a tumor suppressor gene by interacting with retinoic acid. Expression of RARβ is reported to be absent or downregulated in tumor tissues, 92 and the RARβ2 promoter is aberrantly methylated in many cancers, including prostate cancer. 93 Several groups reported that frequencies of methylation of the RARβ2 promoter range from 40% to 84% of primary prostate cancers but rarely in normal prostate tissues or BPH samples. 17, 18, 28, 39, 93, 94 Moderately high frequency of RARβ promoter methylation was observed in 35% of urine samples. 27 In addition, the RARβ2 promoter is methylated in 20% of pro-static intraepithelial neoplasia (PIN) samples. Therefore, RARβ2 gene methylation may be an ideal biomarker candidate for early detection of prostate cancer. 18, 93 Glutathione S-transferase P1 (GSTP1) is involved in the detoxifying process and elimination of potentially genotoxic foreign compounds by conjugating glutathione into toxic chemicals. These processes protect prostate cells from DNA adducts and carcinogenesis. Thus, defective GSTP1 activity may increase DNA mutations, thereby possibly increasing the risk of prostate cancer. 95 Because of its consistently frequent hypermethylation in the promoter region in prostate cancer, GSTP1 is perhaps the most studied gene in prostate cancer. Lee et al 96 first reported a high frequency of GSTP1 hypermethylation in prostate tumor tissues. 96 Since then, numerous studies confirmed similar results. Methylation of the GSTP1 promoter region occurs in 36% to 100% of tumor tissues. [17] [18] [19] [20] [21] [22] 28, 39, 41, [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] However, this methylation is rarely detected in normal prostate or BPH tissues. GSTP1 methylation was also detected consistently with high frequency in urine samples, blood, and ejaculates of prostate cancer patients, while either low or no methylation was detected in the samples from healthy controls. 27, 25, 106, 107 These different frequencies of GSTP1 promoter hypermethylation between tumor and normal prostate tissues make an ideal biomarker for prostate cancer.
Retinoids have an antitumorigenesis function and are involved in cell growth and differentiation. Their functional effects are mainly mediated by retinol-binding protein (RBP1). The role of RBP1 expression in carcinogenesis is not yet defined. However, the low expression of RBP1 by promoter methylation has been associated with the malignant tumor tissues, including prostate. 108, 109 Two studies reported that RBP1 promoter hypermethylation was found in 47% and 81% of tumors. No BPHs and normal prostate tissues were methylated. 20, 109 Tazarotene-induced gene 1 (TIG1) is frequently silenced in prostate tumors. This gene, also known as retinoid acid (RA) receptor-responsive 1 gene, was first identified as an RA-responsive gene. Several investigators reported that TIG1 was frequently methylated (53% to 96%) in prostate tumors, but in normal tissue or benign hyperplasia, TIG1 methylation was either absent or low. 59, 66, 94, 110, 111 Zhang et al 94 further found that the methylation of TIG1 and RARβ was positively correlated. Therefore, it is possible that the methylation of the retinoid response gene TIG1 occurred in response to the methylation and inactivation of RARβ. Ellinger et al 112 analyzed the diagnostic and prognostic possibilities of methylation analysis in cell-free serum DNA of patients with prostate cancer. They found that hypermethylation in TIG1 was more frequent in prostate cancer patients (10%) compared to BPH (0%) and healthy individuals (0%). 59 The detection of hypermethylation in cell-free serum DNA may allow the specific diagnosis of prostate cancer.
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Tumor Cell Invasion and Metastasis Genes
Metastasis is an extremely complicated process that occurs through a series of sequential steps involving invasion, transport, adhesion at a distant site, and outgrowth into a secondary organ. Although metastases are the cause of 90% of human cancer deaths, little is known about the genetic and biochemical determinants of metastasis.
The methylated adenomatous polyposis coli (APC) gene causes familial adenomatous polyposis, which is an inherited disorder characterized by extensive colon polyps and the development of colorectal cancer in early adulthood. The APC complex is known to function as a gatekeeper in the cell, preventing the transcription of gene products that promote cell proliferation and survival rather than differentiation and apoptosis. 114 Hypermethylation of APC implies silencing of this gatekeeper, making the cell vulnerable to further epigenetic and genetic changes and thus progression toward the development of invasive cancer. APC promoter methylation is common in various human tumors, especially in the colon. Most studies found a prevalence of 27% to 100% in prostate cancer tissue but only 5% to 6% in non cancerous tissue. 17, 19, 20, 22, 27, 28, 45, 48, 55, 66, [115] [116] [117] [118] Recent studies found that methylation in APC is associated with progression of prostate cancer. 48, 115, 118 In two small cohorts of prostate cancer patients, a 3-fold statistically significantly increased hazard ratio (HR) for promoter methylation in APC has been reported among the patients who experienced prostate-specific antigen (PSA) recurrence, metastasis, or death. 48, 115 Richiardi et al 118 found that hypermethylation in the promoter of the APC gene is involved in prostate cancer progression using large survival analysis.
Matrix metalloproteinases (MMPs) are proteolytic enzymes that degrade of the extracellular matrix and the basement membrane. High expressions of these enzymes have been associated with tumor growth, invasion, and tumor-induced angiogenesis. 119 These pathways are controlled by the balance between the levels of the MMPs and tissue inhibitors of metalloproteinases (TIMPs). 120 TIMP-2 and TIMP-3 are two of the frequently investigated members of this family because of their involvement in cancer progression and metastasis in a variety of human cancers. [121] [122] [123] [124] [125] [126] [127] Pulukuri et al 123 observed that 25 (60%) of 42 prostate tumors were methylated in TIMP-2 compared with 5 (16%) of 32 normal prostate samples. However, these results were not confirmed by a previous study. 124 Ross et al 124 found that TIMP-2 was expressed in a majority of prostate tumors and correlates with clinical stages. Contrary to the earlier study that indicated antitumor effects, TIMP-2 expression appears to have a tumor-promoting role in prostate cancer and warrants further investigation. 124 High expression of TIMP-3 reduces metastasis, induces apoptosis, increases drug sensitivity, and in hibits tumor growth. [125] [126] [127] A low expression by promoter methy lation of TIMP-3 has been associated with poor out-comes. 128 The promoter region of TIMP-3 was found to be methylated in 97% of prostate tumors. 20 However, other studies reported low (6% and 0%) frequencies of TIMP-3 methylation. 18, 19 Two studies found TIMP-3 promoter methylation in 37% and 41% of urine sediments from prostate cancer patients. 27, 35 As a diagnostic marker in urine DNA, TIMP-3 may be limited by a persistent low frequency of methylation in normal controls.
Others tumor metastasis genes -Caveolin-1 (CAV1), E-cadherin (CDH1), H-cadherin (CDH13), EPHA7, and S100A2 -are often downregulated in prostate tumor tissues than in adjacent normal tissues due to methylation. 17, 19, 27, 28, [39] [40] [41] [42] 91, [129] [130] [131] [132] [133] [134] [135] Gene silencing of CAV1, CDH1, and CDH13 is associated with clinical features of prostate cancer. 131, 133, 136, 137 These data suggest that the methylation status of CAV1 and CDH1 not only is a potential biomarker for prostate cancer, but also may be a predictive marker of outcome. 136 However, two studies reported that methylation of CDH1 promoter could not be detected in prostate cancer samples.
19,41 S100A2 methylation was seen in 75% of cases of nonmalignant tissues and in 100% of cases of BPH.
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Conclusions
Although a few large-scale genome-wide analyses of epigenetic variations are currently ongoing, most published studies are small-scale with a retrospective design. Therefore, meta-analyses or large studies should be performed to obtain the complete extent and pattern of differential DNA methylation in the promoter region in the critical genes. Since epigenetic changes are involved in the carcinogenesis and progression of prostate cancer, information of these epigenetic changes may provide a clue for better diagnostic, prognostic, and predictive modalities than existing options. The ultimate goals of these epigenetic studies are to improve patient outcomes and enhance quality of life. A number of clinical trials and therapies are targeting methylated genes. Unlike DNA somatic mutations, DNA methylations are reversible. Thus, hypermethylated tumor-suppressor genes can be reactivated with drugs. Several demethylating agents such as 5-azacytidine (Vidaza) and 5-aza-2′-deoxycytidine (decitabine) have been approved as treatments for myelodysplastic syndrome (MDS) and leukemia. [138] [139] [140] Some MDS patients treated with 5-azacytidine showed a significant survival benefit. 141 However, a major limitation of these therapies is their nonspecific target approach, which may induce unintended side effects. Therefore, not only tumor suppressor genes but also silenced oncogenes by methylation can be reactivated. Future studies should focus on developing drugs that can target specific genes.
